Compare Dow Inc (DOW) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Inc vs Recursion Pharmaceuticals Inc — how do they compare? Dow Inc trades at $29.72 (market cap $21.85B), while Recursion Pharmaceuticals Inc trades at $3.32 (market cap $1.78B). The key difference: Dow Inc is far larger — about 12.3× Recursion Pharmaceuticals Inc's market cap, and Dow Inc pays a 4.62% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| DOW | RXRX | |
|---|---|---|
Market Cap | $21.85B | $1.78B |
Sector | Basic Materials | Health |
52-Week High | $41.87 | $6.79 |
52-Week Low | $20.65 | $2.84 |
Enterprise Value | $37.62B | $1.19B |
Dividend Yield | 4.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOW trades at $30.37, up 4.62% on the day, with a bullish technical signal from moving averages despite negative profitability metrics. The company reported a net loss of $2.62 billion for 2025, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights Dow's inclusion in discussions about materials stocks benefiting from oil price spikes, while cash flow trends show improved net cash generation in 2025.
The outlook is mixed: analyst consensus suggests 19% upside to the $36.11 price target, but high P/E of 75.93 and negative margins pose valuation risks. Key opportunities include dividend payments and earnings beats, while risks involve sustained profitability challenges and rising debt-to-asset ratios nearing 30%.
RXRX trades at $3.30, down 7.3% today, with bearish technical signals from moving averages and oscillators. The clinical-stage biotech shows severe financial strain with a -851.51% net income margin and negative cash flow from operations of -$372M in 2025, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights AI-driven drug discovery potential but questions commercial viability.
Despite analyst consensus price target of $7.83 suggesting 137% upside, high cash burn and unproven business model pose substantial risk. Investment appeal hinges on successful drug development milestones, but current fundamentals indicate speculative positioning suitable only for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
